Silence Therapeutics (FRA:XRP2) Change In Receivables : €-10.41 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Change In Receivables?

Silence Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was €-9.59 Mil. It means Silence Therapeutics's Accounts Receivable increased by €9.59 Mil from Dec. 2023 to Mar. 2024 .

Silence Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €-1.69 Mil. It means Silence Therapeutics's Accounts Receivable increased by €1.69 Mil from Dec. 2022 to Dec. 2023 .

Silence Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was €9.52 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Silence Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 59.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Silence Therapeutics's liquidation value for the three months ended in Mar. 2024 was €103.32 Mil.

Silence Therapeutics Change In Receivables Historical Data

The historical data trend for Silence Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Change In Receivables Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.01

-32.37

32.34

-1.25

-1.69

Silence Therapeutics Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.91	-12.94	11.99	0.13	-9.59

Silence Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.41 Mil.

Silence Therapeutics (FRA:XRP2) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Silence Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	9.516	/	14.503	*	91
=	59.87

2. In Ben Graham's calculation of liquidation value, Silence Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Silence Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	178.569	-	82.387	+	0.75 * 9.516	+	0.5 * 0
=	103.32

Silence Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (FRA:XRP2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (FRA:XRP2) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SLN:USA SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Silence Therapeutics (FRA:XRP2) Headlines

No Headlines